Fingolimod: Clinical Trials

11 trials of Fingolimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 unknown, 1 enrolling by invitation, 1 recruiting. 11 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Unknown 3, Enrolling by invitation 1, Recruiting 1, Withdrawn 1
Phase 32Completed 1, Recruiting 1
Phase 11Unknown 1

Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis
Phase 2 / Phase 3RecruitingTG Therapeutics, Inc.2402026-07-012026-10-29
Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage
Fingolimod - Intracerebral Hemorrhage
Phase 1 / Phase 2UnknownTang-Du Hospital402023-10-112023-10-18
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
Fingolimod, Placebo - Interstitial Fibrosis, Kidney Transplant; Complications
Phase 2Enrolling by invitationThe Methodist Hospital Research Institute202022-07-282025-03-14
Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke
Fingolimod, Placebo - Stroke, Inflammation
Phase 2UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine1182021-01-152023-04-18
Fingolimod in Endovascular Treatment of Ischemic Stroke
Fingolimod - Stroke Inflammation
Phase 2UnknownNing Wang, MD., PhD.302020-11-122022-04-13
Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
Fingolimod - Stroke, Inflammation
Phase 2WithdrawnSecond Affiliated Hospital, Zhejiang University, School of Medicine2016-11-012021-07-22
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
Fingolimod, Fish Oil, Placebo (for Fish Oil) - Multiple Sclerosis
Phase 2 / Phase 3CompletedIsfahan University of Medical Sciences502015-04-012019-05-14
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Gilenya, Placebo - Amyotrophic Lateral Sclerosis
Phase 2CompletedMassachusetts General Hospital302013-08-012016-07-01
Fingolimod in Schizophrenia Patients
Fingolimod, placebo - Schizophrenia
Phase 2CompletedIndiana University402013-01-012019-04-16
Efficacy and Safety of FTY720 for Acute Stroke
Fingolimod - Stroke, Vascular Accident
Phase 2CompletedTianjin Medical University General Hospital222012-10-012018-10-17
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Fingolimod - Multiple Sclerosis
Phase 2CompletedNovartis1432008-04-012013-09-04

Conditions studied

Ischemic Stroke (3)  ·  Stroke (3)  ·  Inflammation (2)  ·  Multiple Sclerosis (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Cerebral Hemorrhage (1)  ·  Fibrosis (1)  ·  Kidney Failure, Chronic (1)  ·  Psychotic Disorders (1)  ·  Pulmonary Fibrosis (1)  ·  Rejection, Psychology (1)  ·  Schizophrenia (1)

Sponsors

Second Affiliated Hospital, Zhejiang University, School of Medicine (2)  ·  Indiana University (1)  ·  Isfahan University of Medical Sciences (1)  ·  Massachusetts General Hospital (1)  ·  Ning Wang, MD., PhD. (1)  ·  Novartis (1)  ·  TG Therapeutics, Inc. (1)  ·  Tang-Du Hospital (1)  ·  The Methodist Hospital Research Institute (1)  ·  Tianjin Medical University General Hospital (1)

Countries

China (4)  ·  United States (4)  ·  Japan (1)  ·  Poland (1)  ·  Slovakia (1)

Top investigators

Alan Breier, MD (1)  ·  Fu-Dong Shi, MD,PhD (1)  ·  James D Berry, MD, MPH (1)  ·  Michael Francis, MD (1)  ·  Min Lou, MD,PhD (1)  ·  Min Lou, PhD, MD (1)  ·  Shaygannejad Shaygannejad, M.D. (1)  ·  Yan Qu (1)

Results publications

PMID 24475777, PMID 25003359, PMID 26202811, PMID 28129749, PMID 35720286

NIH funding

2025 (1)